Abstract
This longitudinal single-center study describes the timing and risk factors for genital human papillomavirus (HPV) disease in women after allogeneic hematopoietic cell transplantation (HCT). Between 1994 and 2014, 109 females underwent HCT of whom 82 surviving transplant for >1 year had regular, comprehensive genital tract assessment and treatment of HPV disease. The cumulative proportions of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.9%, respectively. Demographic, disease-related factors, chronic GvHD (cGvHD) and its treatment were analyzed for their association with persistent, multifocal or severe genital HPV disease. Pre-transplant HPV disease was strongly associated with any posttransplant HPV (odds ratio (OR)=6.5, 95% confidence interval (CI)=1.65–25.85, P=0.008). Having either extensive or genital cGvHD was associated with increased risk of any HPV disease (OR=5.7, 95% CI=1.90–17.16, P=0.002) and a higher risk for severe genital dysplasia (CIN II–III/VIN II–III; OR=13.1, 95% CI=1.59–108.26, P=0.017), but no one developed HPV-related genital cancer. Persistent, multifocal or severe HPV disease occurred more frequently than in healthy populations. Women with extensive cGvHD, genital cGvHD or pre-transplant HPV are at greatest risk for post-transplant HPV disease. Early initiation of annual screening, comprehensive genital tract assessment and active management are cornerstones of their gynecology care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S . Human papillomavirus and cervical cancer. Lancet 2007; 370: 890–907.
Schiffman M, Wentzensen N . From human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116: 177–185.
Trottier H, Franco EL . The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 (Suppl 1): S1–15.
Parkin DM, Bray F . Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 (Supplement 3): S11–S25.
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607–615.
Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015; 107: djv086.
Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336–1343.
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS . Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123–137.
Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486–494.
Doorbar J . Latent papillomavirus infections and their regulation. Curr Opin Virol 2013; 3: 416–421.
Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ . Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation—implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008; 14: 1072–1075.
Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230–2239.
Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738–744.
Morton LM, Saber W, Baker KS, Barrett AJ, Bhatia S, Engels EA et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: the Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant 2016; S1083-8791: 30331–30337.
Bhatia S, Francisco L, Carter A, Sun C-L, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.
Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE . Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant 2016; 51: 83–88.
Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802–3811.
Wang Y, Brinch L, Jebsen P, Tanbo T, Kirschner R . A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 747–753.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50: 1013–1023.
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337–341.
Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114–2119.
Li Z, Mewawalla P, Stratton P, Yong ASM, Shaw BE, Hashmi S et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer 2015; 121: 4124–4131.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147–172.
Sri T, Merideth MA, Pulanic TK, Childs R, Stratton P . Human papillomavirus reactivation following treatment of genital graft-versus-host disease. Transpl Infect Dis 2013; 15: E148–E151.
Aldabagh B, Angeles JGC, Cardones AR, Arron ST . Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol Surg 2013; 39: 1–23.
Braaten KP, Laufer MR . Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 2008; 1: 2–10.
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–428.
Ault KA . Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006; 2006 (Suppl): 40470.
Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 1777–1784.
Moscicki A-B, Schiffman M, Kjaer S, Villa LL . Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24: S42–S51.
Acknowledgements
This study was supported by Intramural Program of National Institutes of Health, NIH Clinical Center, National Heart, Lung and Blood Institute, and Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Shanis, D., Anandi, P., Grant, C. et al. Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. Bone Marrow Transplant 53, 78–83 (2018). https://doi.org/10.1038/bmt.2017.210
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.210